At Avro Life Sciences, we are developing a unique, transdermal patch for the paediatric delivery of antihistamines. This will be a fun and easy to use, aesthetically pleasing, medicated sticker that you place on your skin. With 1 in 3 children across North America suffering from seasonal or pet allergies, our mission is to develop a simple and effective way for your kids to get their medication without the hassle.
Protects the patch from the outer environment.
Antihistamine solution in direct contact with the slow release membrane
Controls the slow release of the drug from the reservoir
Adheres the patch to the skin. The enhancer increases bioavailability of the drug.
Keean’s affinity for STEM and passion for pharmaceuticals sparked the inception of Avro Life Science. As an PharmD student, Keean is one of twenty-four students nationally, to hold the Conditional Admission to Pharmacy Status at the University of Waterloo. With experience in numerous healthcare settings, from major hospitals to retail pharmacies, Keean oversees all day-to-day management, as well as long term decisions for Avro Life Science, as the Chief Executive Officer.
As our Chief Technical Officer, Shak is the brain behind all of the science and technology that goes into creating novel transdermal patches. Shak is a B.ASc candidate at the University of Waterloo in Nanotechnology Engineering, with a passion for everything STEM related. With three publications under his belt, one of them being in Nature Magazine, Shak thrives on innovation and new discoveries.
As a clinically trained pharmacist with a masters degree from the Harvard School of Public Health, Dr. Mamdani formerly worked as the Director of US Outcomes Research for Pfizer. With his expert knowledge of pharmaceuticals, epidemiology, and quantitative methods, Dr. Mamdani is currently the Director of the St. Michael's Hospital Centre for Healthcare Analytics Research and Training (CHART). He is a Professor in the University of Toronto Faculty of Pharmacy, the Faculty of Medicine, and the Institute for Health Policy, Management, and Evaluation. Dr. Mamdani is also a member of the Human Drug Advisory Panel of the Patented Medicine Prices Review Board (PMPRB).
Dr. Shawn Wettig is the Associate Director for Research and Graduate Studies and an Associate Professor at the University of Waterloo School of Pharmacy. Dr. Wettig’s research focuses on the design, synthesis and characterization of novel surfactants with an eye toward their application in drug delivery. With experience in transdermal drug delivery and nanomedicine, Dr. Wettig also holds cross appointments with the Department of Chemistry and Chemical Engineering
Velocity Science Lab, Earth Sciences and Chemistry 319, 200 University Ave W, Waterloo, ON N2L 3G1